Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

@article{Yokota2008EfficacyAS,
  title={Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.},
  author={Shunpei Yokota and Tomoyuki Imagawa and Masaaki Mori and Takako Miyamae and Yukoh Aihara and Shuji Takei and Naomi G. Iwata and Hiroaki Umebayashi and Takuji Murata and Mari Miyoshi and Minako Tomiita and Norihiro Nishimoto and Tadamitsu Kishimoto},
  journal={Lancet},
  year={2008},
  volume={371 9617},
  pages={998-1006}
}
BACKGROUND Systemic-onset juvenile idiopathic arthritis does not always respond to available treatments, including antitumour necrosis factor agents. We investigated the efficacy and safety of tocilizumab, an anti-interleukin-6-receptor monoclonal antibody, in children with this disorder. METHODS 56 children (aged 2-19 years) with disease refractory to conventional treatment were given three doses of tocilizumab 8 mg/kg every 2 weeks during a 6-week open-label lead-in phase. Patients… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS